Even though acute stroke care has improved, for example by large-scale application of recombinant tissue plasminogen activator (rTPA) [1], [2] and organized interdisciplinary inpatient stroke care [3], and although mortality rates have been decreasing [1], a large number of patients still remain disabled regardless of the time that has elapsed poststroke. The gene discussed is PLAT; the disease is stroke disorder.